Programmed death ligand-1 expression in non-small cell lung cancer. - Wikidata - wikimedia - TriplyDB

Programmed death ligand-1 expression in non-small cell lung cancer.

Programmed death ligand-1 expression in non-small cell lung cancer.

http://www.wikidata.org/entity/Q34384255

about

PD-L1 expression in human cancers and its association with clinical outcomes Towards tumor immunodiagnostics A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting Epstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune Response Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis Advances in immunotherapy for treatment of lung cancer Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer Predictive biomarkers in precision medicine and drug development against lung cancer Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications Immunotherapy in the treatment of non-small cell lung cancer PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis.PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations Prospects of immune checkpoint modulators in the treatment of glioblastoma PD-L1 and Survival in Solid Tumors: A Meta-Analysis Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor.Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1 PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.Programmed cell death ligand 1 expression in osteosarcoma.Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.Nivolumab in NSCLC: latest evidence and clinical potential Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma.Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.

P2860

Q26738361-E28D13F4-D6B5-40BA-BA29-4A576F6755F6 Q26738691-C0BC1E3C-8C5E-4B37-8BCB-A0F60783CFC3 Q26738729-D98B804A-1B96-425C-A9A0-B8B91A8C0F6E Q26741101-4846E77A-2A76-4D77-A56E-F6218D6E2458 Q26745516-BBBECAEC-6D57-44BE-8FBA-8C97D65FE62B Q26747792-700D5665-5102-4253-B088-170BDC93C27E Q26751029-5B38A93E-CAD9-4EEB-8120-40E2F7D624BC Q26769728-912C6066-4DC1-4DE1-9028-9813DBBFF4EA Q26778790-CD3E013C-00AE-41EA-8D14-5F1CB32DC2C9 Q26798047-4F182119-93B4-4463-9669-DBA6BE2ABBDA Q26824536-C4825B89-6268-46F9-9E96-D84998899E56 Q26996518-7B8EFD50-B8C8-46C9-94B8-8B2470EC758F Q27000382-A7B2CFC0-E544-4DEF-A021-C0E7B520F45E Q27853205-4941FE75-E47A-4AF4-916D-0E7E744D2CBF Q27853291-2A1BFA91-B3DC-4706-BE4F-019E1CF74431 Q28075712-F9A25EDE-A63C-4834-A2D5-53B1DDC455F7 Q28081371-62ECF80E-C288-4F1F-9066-6995C5F77E45 Q28084090-9483BB24-72AF-460D-AA59-6A675C017270 Q28084766-A2B90B5B-354C-4BA1-A219-D43A999841A2 Q29617774-37B818D5-6C47-466A-A062-190E63A08EA8 Q29620902-925676EE-4899-424E-A79B-9558832A4375 Q30489890-94A9FF17-6AD2-4B95-8A2E-84917FB4944B Q31137039-B763B2ED-D3D9-47CF-9785-125D50D39187 Q33586463-C9EE5421-59F2-41D7-80B2-B8DDA1AC6D63 Q33607407-A5D3E6A0-16E9-44C3-82D1-E2C971276B1F Q33644049-16211F2F-E2E8-4C0F-9E5E-9FA9C5FA92E3 Q33658400-1EBC78B8-05E2-49DB-A08B-AA9A74318707 Q33688849-B4B9F9A3-D998-468C-933F-98F922CB7288 Q33788049-DA041066-890A-46B2-8CE0-92BCD710B8E6 Q33848154-65455497-93BB-43F5-AABA-DD7ED10ECF50 Q34270064-BC04EAFE-61A9-490F-BEEA-8A6C06056601 Q34454922-815E6A78-EB81-4E49-8361-F56BD9F4AC5A Q34466452-C55B5283-0530-46D7-8A69-97DB44E2C545 Q34522172-B77FA4A9-800C-4650-BF1E-545D8DFCC100 Q34623884-6101CDC8-C9BA-4E44-89C7-C7E20CF1C498 Q34669751-04842D87-61AA-4EC3-A36E-DA3A067EB941 Q35067875-EBABF55F-64EC-4B9E-A620-7E7DC5B94D34 Q35143602-955F5CA2-E622-4F74-8ACB-AD50FC193988 Q35182037-E7A2D2F9-6C6F-47B3-8A1C-372E779A8FA2 Q35256558-B0E35AEA-10B9-4100-84E0-62F8B99DA59F

P2860

Programmed death ligand-1 expression in non-small cell lung cancer.

http://www.wikidata.org/entity/Q34384255

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Programmed death ligand-1 expression in non-small cell lung cancer.

@ast

Programmed death ligand-1 expression in non-small cell lung cancer.

@en

Programmed death ligand-1 expression in non-small cell lung cancer.

@nl

type

label

Programmed death ligand-1 expression in non-small cell lung cancer.

@ast

Programmed death ligand-1 expression in non-small cell lung cancer.

@en

Programmed death ligand-1 expression in non-small cell lung cancer.

@nl

prefLabel

Programmed death ligand-1 expression in non-small cell lung cancer.

@ast

Programmed death ligand-1 expression in non-small cell lung cancer.

@en

Programmed death ligand-1 expression in non-small cell lung cancer.

@nl

P1433

Q34384255-6E718F2F-33E9-4B4F-B746-1CD04C5C1C05

P1476

Q34384255-D9FF3CB9-A225-4C94-BF65-029ADD6F67D1

P2093

Q34384255-2DC56D14-3AE4-44C9-8835-F7D2390A71AC

Q34384255-7E491A92-179E-4775-BB83-50DB35FFAF5A

Q34384255-913BEA33-E876-4E41-8431-E17A6CB384CB

Q34384255-B2C8CCF0-47F6-494C-9765-FBD3C9ABDA2F

Q34384255-CA369213-94AC-4F62-8D40-A59BC2C64F65

Q34384255-D2E74FF0-0A6C-4AB7-8AEF-0305FF561674

Q34384255-F5079DE5-895E-4AB3-BB78-EBA2389A7BC5

P2860

Q34384255-1258BFAB-6F68-4816-8CC2-A7349BDD6200

Q34384255-1897FD0E-8AD4-4974-B0E7-E8EC4232B93D

Q34384255-3F35D5C1-58CA-4582-82E4-DF0A15682843

Q34384255-4BFE128B-9406-4A0B-BE84-C99A238C38DE

Q34384255-5AD92BFF-1C16-430D-BB11-CB8D786E171C

Q34384255-6FC5150A-19BD-49E3-9284-AD5297F0FD9B

Q34384255-7B8D06BD-847C-4045-AC3F-59D4906609D0

Q34384255-7E010968-E594-4F78-8466-1CD06D2E7742

Q34384255-82530B96-3212-4136-AAAB-F5D29AC9AD0E

Q34384255-82AD61CB-E4D7-4B6F-8EA0-BF5C42729A08

P2888

Q34384255-649A3E96-25CE-41C0-B3C1-6BEFFE67C1FC

P304

Q34384255-759C4B32-0E04-4AA1-80F7-FBB24F0EC172

P31

Q34384255-CDC9F192-4B7C-4A4C-92A4-EE975D1B074A

P356

Q34384255-7475BA71-23DA-4A2A-A57B-ECBF8955ECC6

P433

Q34384255-CD7E24D9-1B85-46F1-AD70-4A32CE198D33

P478

Q34384255-74D72680-5829-4C48-9481-261F33FD7A79

P50

Q34384255-471F0B1A-6ECA-4040-9B46-B82C5A196820

Q34384255-C376957D-373A-4996-A57F-5BD93F42E637

Q34384255-F6DAB681-E829-4A7A-9090-A0868AC24C73

P577

Q34384255-F494B8D0-E8DF-4B4F-BC09-620A4F5C6084

P5875

Q34384255-6F0F9CC6-1DFC-4434-819E-11E7345BBBB8

P6179

Q34384255-B6241B45-D7C2-4991-A944-78C42B68A4CE

P698

Q34384255-136D96BB-D4A5-433A-BA06-AEBB3789CD68

P932

Q34384255-DAC4B572-7636-4B3E-93CF-E73FFACCEC0C

P356

LABINVEST.2013.130

P1433

Laboratory Investigation

P1476

Programmed death ligand-1 expression in non-small cell lung cancer.

@en

P2093

Daniel E Carvajal

http://www.w3.org/2001/XMLSchema#string

David L Rimm

http://www.w3.org/2001/XMLSchema#string

Konstantinos N Syrigos

http://www.w3.org/2001/XMLSchema#string

Lieping Chen

http://www.w3.org/2001/XMLSchema#string

Scott N Gettinger

http://www.w3.org/2001/XMLSchema#string

Valsamo K Anagnostou

http://www.w3.org/2001/XMLSchema#string

Vamsidhar Velcheti

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity.

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.

The new lung cancer staging system.

P2888

labinvest.2013.130

P304

107-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LABINVEST.2013.130

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

Kurt A Schalper

P577

2013-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258444478

http://www.w3.org/2001/XMLSchema#string

P6179

1024707845

http://www.w3.org/2001/XMLSchema#string

P698

24217091

http://www.w3.org/2001/XMLSchema#string

P932

6125250

http://www.w3.org/2001/XMLSchema#string